Toi osakkeiden printtaaminen Faronille itselleen on jokaisena vuonna toistunut. Sitten niitä on suunnatuissa anneissa myyty n. 15 % alennuksella. Sillä tavalla Faronin toiminta on rahoitettu. Se, että Faron printtaa osakkeita, ei vaikuta vielä mitenkään yhtiön arvoon. Jokainen niistäkin osakkeista on meidän osakkeenomistajien omistuksessa, koska omistamme yhtiön osakkeineen. Se, jos niitä myytäisiin samaan hintaan, kuin yhtiön arvo on, ei vieläkään vaikuttaisi omistustemme arvoon, koska sen jälkeen omistamme myös rahavarat, jotka on saatu myymällä ne uudet osakkeet. Suuremmat varat vain jaetaan useamman osakkeen kesken. Suuremmat varat mahdollistavat arvonluonnin lääkekehityksen kautta, mikä on Faronin toiminnan idea.
Jos yhtiön ”näkymät” heikentyvät (lääkekehityksen näkymät ovat kai ennemmin parantuneet), alkaa tapahtua. Kierre epäluulon ja osakkeen kurssinlaskun välillä voi alkaa, uudet osakkeet joudutaan myymään markkinalle halvemmalla hinnalla kuin vanhat omistajat ovat osuutensa ostaneet, mm. @Sperakartio antien alea purnasi. Sitä sitten kutsutaan omistuksen laimentumiseksi. Epäluulo sai nyt kurssin alas ja sen vuoksi printteri käy kuumempana kuin edellisvuosina 2023ja 2022 (alla). Jos printtausvaltuutus on tietylle määrälle osakkeita, ei se tarkoita kuitenkaan, että koko valtuutus käytetään, se on vain sen hetkinen maksiminäkymä.
———————————-
AGM v 2023:
”16. Authorising the Board to decide on the issuance of shares, options or other special rights entitling to shares
The Board proposes that the AGM authorise the Board to resolve by one or several decisions on issuances of shares, options or other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, which authorisation contains the right to issue new shares or dispose of the Company’s own shares in the possession of the Company. The authorisation would consist of up to twelve million five hundred thousand (12,500,000) new shares in the aggregate (including shares to be received based on options or other special rights), which corresponds to approximately twenty (20) per cent of the existing shares and votes in the Company, as well as the conveyance of up to the same maximum number (twelve million five hundred thousand (12,500,000)) of treasury shares in the possession of the Company.
In practise, the above authorisation includes that the Board may first resolve on one or several share issues (up to the maximum number of twelve million five hundred thousand (12,500,000) new shares) without consideration to the Company itself and then further convey such treasury shares (up to the maximum number of twelve million five hundred thousand (12,500,000) shares) against consideration.
The authorisation would not exclude the Board’s right to decide on the issuance of shares, options or other special rights entitling to shares in deviation from the shareholders’ pre-emptive rights.
The authorisation is proposed to be used for material arrangements from the Company’s point of view, such as financing (including, without limitation, issuance of warrants under the funding agreement with IPF Partners announced on February 28, 2022) or implementing business arrangements, investments or for other such purposes determined by the Board in which case a weighty financial reason for issuing shares, options or other special rights entitling to shares, and possibly deviating from the shareholders’ pre-emptive rights, would exist.
For the sake of clarity, it is noted that in no circumstances can the total number of new shares to be registered under this authorisation exceed twelve million five hundred thousand (12,500,000) new shares in aggregate.”
————————————-
AGM 2022:
”15. Authorising the Board to decide on the issuance of shares, options or other special rights entitling to shares
The Board proposes that the AGM authorise the Board to resolve by one or several decisions on issuances of shares, options or other special rights entitling to shares referred to in Chapter 10, Section 1 of the Companies Act, which authorisation contains the right to issue new shares or dispose of the shares in the possession of the Company. The authorisation would consist of up to ten million six hundred thousand (10,600,000) shares in the aggregate (including shares to be received based on options or other special rights), which corresponds to approximately twenty (20) per cent of the existing shares and votes in the Company.
The authorisation would not exclude the Board’s right to decide on the issuance of shares, options or other special rights entitling to shares in deviation from the shareholders’ pre-emptive rights. The authorisation is proposed to be used for material arrangements from the Company’s point of view, such as financing (including, without limitation, issuance of warrants under the funding agreement with IPF Partners announced on February 28, 2022) or implementing business arrangements, investments or for other such purposes determined by the Board in which case a weighty financial reason for issuing shares, options or other special rights entitling to shares, and possibly deviating from the shareholders’ pre-emptive rights, would exist.
The Board would be authorised to resolve on all other terms and conditions of the issuance of shares, options or other special rights entitling to shares.
The authorisation would be effective until 30 June 2023.
16. Authorising the Board to decide on the issuance of shares without consideration to the Company
The Board proposes that the AGM authorise the Board to resolve by one or several decisions on a share issue without consideration to the Company itself. The authorisation would consist of up to ten million six hundred thousand (10,600,000) shares in the aggregate, which corresponds to approximately twenty (20) per cent of the existing shares and votes in the Company.
The authorisation would not exclude the Board’s right to decide on the issuance of shares in deviation from the shareholders’ pre-emptive rights. The Board would be authorised to resolve on all other terms and conditions of the issuance of shares, including the right to issuances without consideration. Issuances without consideration require that there is an especially weighty financial reason for doing so from the Company’s point of view and observing the interests of all the shareholders of the Company.
The authorisation would be effective until 30 June 2023. The proposed authorisation does not revoke the share issue authorisations granted to the Board otherwise during this AGM.”